NewcelX rises after raising funds at premium to boost diabetes program

ReutersApr 1, 2026 11:36 AM

Shares of biotech firm NewcelX NCEL.O rise 13.7% to $2.41 premarket

Co says it raised funds via a private share placement priced 30% above its last close

NewcelX is developing stem cell treatments for Type 1 diabetes, a condition where the body cannot make insulin to control blood sugar - NCEL

Co says it sold ~491,000 shares and warrants for ~687,000 more shares, with existing shareholders participating

Proceeds, along with a previously announced $25 million equity line, will fund its lead diabetes program NCEL-101 and other pipeline work - NCEL

Co says deal expected to close around April 15, subject to standard conditions

As of last close, stock up ~12% YTD

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Tradingkey

Recommended Articles

From Computing Power to Efficiency: OpenAI VS Claude Code

TradingKey - On April 1, 2026, the AI industry witnessed a dramatic contrast: OpenAI completed the largest financing round in Silicon Valley history amid surging capital enthusiasm, while the memory spot market suffered a “cliff-like” plunge, sending a chill through the sector. These seemingly contr

South Korea Stocks Surge 9% with Double Circuit Breakers as Analysts Warn of a False Dawn

TradingKey - On Wednesday (April 1), South Korea's KOSPI index surged by as much as 9% in late trading, breaking above the 5,500-point mark and ending a four-session losing streak. As KOSDAQ 150 index futures rose 6%, the Korea Exchange triggered a circuit breaker mechanism, suspending program tradi

Buffett Admits Selling Apple Early, Can Apple Stock Price Still Rise? Need to Watch These Three Signals

TradingKey — Warren Buffett admitted that trimming his stake in Apple was premature. This statement garnered market attention not only because gains have exceeded $100 billion, but more importantly, because it highlights a more practical issue: once a company becomes sufficiently successful and mass

What Is Palantir? Can Palantir’s Stock Price Return to $200 in 2026?

TradingKey - In today’s highly competitive technology landscape, Palantir (PLTR), as a company with a core focus on big data and artificial intelligence, has garnered widespread attention through its unique technological advantages and market positioning.

Bitcoin Price Analysis: What Is to Stop BTC from Making Another Run at All-Time Highs in 2026?

This strategic analysis covers institutional BTC price targets from JPMorgan and Fidelity, the impact of the U.S. Strategic Reserve, and whether the four-year cycle is broken. Stay updated on BTC to USD trends and key market risks.

Tradingkey

KeyAI

